ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
Davis Polk advised ADC Therapeutics SA in connection with a registered secondary offering of 12,000,000 of its common shares by a selling shareholder. ADC Therapeutics is listed on the New York Stock Exchange under the ticker symbol “ADCT.”
ADC Therapeutics is a commercial-stage biotechnology company helping to improve the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London, the San Francisco Bay Area and New Jersey.
The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar, associates David Li and Benjamin Guillon and counsel Chris Van Buren. Partner David R. Bauer and associate David A. Frey provided intellectual property advice. Partner Kara L. Mungovan and associate Michelle Zhao provided tax advice. All members of the Davis Polk team are based in the New York office.